(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-1.87% $ 1.050
Live Chart Being Loaded With Signals
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...
Stats | |
---|---|
Tagesvolumen | 114 913 |
Durchschnittsvolumen | 109 219 |
Marktkapitalisierung | 53.79M |
EPS | $0 ( 2024-03-19 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-06-12 |
Last Dividend | $0.0470 ( 1995-06-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.23 |
ATR14 | $0.00300 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Cannon Kara | Buy | 150 000 | Common Stock |
2024-02-21 | Cannon Kara | Buy | 10 640 | Common Stock |
2024-02-21 | Cannon Kara | Sell | 5 823 | Common Stock |
2024-02-23 | Eckert Patricia | Buy | 75 000 | Stock Option (to acquire shares of Common Stock) |
2024-01-31 | Pully Steven J | Buy | 79 365 | Common Stock |
INSIDER POWER |
---|
88.53 |
Last 85 transactions |
Buy: 4 325 861 | Sell: 177 248 |
Volumen Korrelation
Enzo Biochem Inc Korrelation
10 Am meisten negativ korreliert | |
---|---|
FPEI | -0.872 |
ASB-PE | -0.868 |
CUBB | -0.868 |
GL | -0.855 |
FLR | -0.852 |
NX | -0.843 |
MBI | -0.836 |
PQDI | -0.832 |
BGSF | -0.832 |
SPNT-PB | -0.825 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Enzo Biochem Inc Korrelation - Währung/Rohstoff
Enzo Biochem Inc Finanzdaten
Annual | 2023 |
Umsatz: | $31.06M |
Bruttogewinn: | $11.57M (37.24 %) |
EPS: | $-1.270 |
FY | 2023 |
Umsatz: | $31.06M |
Bruttogewinn: | $11.57M (37.24 %) |
EPS: | $-1.270 |
FY | 2022 |
Umsatz: | $107.07M |
Bruttogewinn: | $41.97M (39.20 %) |
EPS: | $-0.460 |
FY | 2021 |
Umsatz: | $117.73M |
Bruttogewinn: | $53.58M (45.51 %) |
EPS: | $0.160 |
Financial Reports:
No articles found.
Enzo Biochem Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0470 | 1995-06-29 |
Last Dividend | $0.0470 | 1995-06-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.82 | -- |
Div. Sustainability Score | 5.02 | |
Div.Growth Potential Score | 0.366 | |
Div. Directional Score | 2.69 | -- |
Year | Amount | Yield |
---|---|---|
1995 | $0.0470 | 0.58% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.333 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.545 | 1.500 | 5.06 | 7.59 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.78 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0444 | -1.500 | 9.26 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 33.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.455 | -0.909 | [0 - 20] |
debtEquityRatioTTM | 0.0621 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -1.203 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.348 | 1.000 | -8.96 | -8.96 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.10 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.129 | 0.800 | -2.47 | -1.977 | [0.5 - 2] |
Total Score | 5.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1.605 | 1.000 | 9.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.545 | 2.50 | 6.82 | 7.59 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.303 | -0.909 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00912 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.47 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.366 |
Enzo Biochem Inc
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.